Monopar Therapeutics
-
Monopar to Announce Long-Term ALXN1840 Data in Wilson Disease at ANA 2025
Monopar Therapeutics will present long-term data on ALXN1840 for Wilson disease at the ANA Annual Meeting on September 14-15, 2025. The pooled analysis of clinical trials (n=255 efficacy, n=266 safety) with a median 2.6-year treatment duration showed sustained neurological and psychiatric improvements. Patients switching from standard of care to ALXN1840 also demonstrated improvement. The drug exhibited a favorable safety profile. ALXN1840 offers a novel mechanism of action by directly binding copper, potentially preventing its accumulation.
